jain.com

Q2 2026 Annualized Run Rate Revenue

Company: Nebius

Subject kind
guidance
Statement date
2026-08-12
Promised amount
3.0 USD billion
Current status
verified

The claim, verbatim

Annualized run rate revenue of $3 billion at end of June, up from $1.9 billion at end of March

Source (primary)

Nebius (NBIS) Q2 2026 Earnings Call Transcript - The Motley Fool (-, news_article)
View cached copy (2026-08-31)Live source ↗Archive.org ↗

Quote: “Annualized Run Rate Revenue -- $3 billion at the end of June, rising from $1.9 billion at the end of March reflecting increased utilization and infrastructure efficiency.”

How we checked this

Checked on October 10, 2026. The cited source supports every part of this claim.

The transcript states ARR reached $3 billion at the end of June, up from $1.9 billion at the end of March.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.fool.com/earnings/call-transcripts/2026/08/19/nebius-nbis-q2-2026-earnings-call-transcript/) in full (56,259 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Nebius (NBIS) Q2 2026 Earnings Call Transcript - The Motley Fool

Quote: “Annualized Run Rate Revenue -- $3 billion at the end of June, rising from $1.9 billion at the end of March reflecting increased utilization and infrastructure efficiency.”

View cached copy (2026-08-31)Live source ↗Archive.org ↗

confirms Nebius Stock Forecast | Palantir Sovereign AI Partnership - Capital.com

Quote: “Annualised run-rate revenue stood at $3bn at the end of June, up from $1.9bn at the end of March.”

View cached copy (2026-09-19)Live source ↗

Record of changes

August 31, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 9, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.